Literature DB >> 9192986

Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms.

K Tamakoshi1, F Kikkawa, O Maeda, N Suganuma, S Yamagata, T Yamagata, Y Tomoda.   

Abstract

We investigated hyaluronidase activity in gynaecological normal and malignant tissues. Hyaluronidase activity in culture medium of tissue specimens was detected by hyaluronic acid zymography and quantified by densitometry. Hyaluronidase activity was shown as one dominant band (molecular weight 65 kDa) at pH 3.5. Hyaluronidase activity was significantly higher in normal ovary (P < 0.05) and normal endometrium (P< 0.05) than in normal cervix. One dominant 65-kDa hyaluronidase was expressed in 100% (14 out of 14) of ovarian cancer tissues and in 91% (10 out of 11) of endometrial cancer tissues. However, hyaluronidase activity was not observed in cervical cancer tissues. Hyaluronidase activity was significantly higher in ovarian (P < 0.001) and endometrial (P < 0.01) cancer tissues than in cervical cancer tissue and was significantly higher in ovarian cancer tissue than in endometrial cancer tissue (P < 0.05). These facts suggest that the cancer cells make use of the original characteristic of the organ to invade and metastasize. Moreover, these results reflect the difference in metastatic forms and are suggestive of a strong relationship between hyaluronidase activity and invasion and metastasis of ovarian and endometrial cancers compared with cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192986      PMCID: PMC2223611          DOI: 10.1038/bjc.1997.308

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.

Authors:  M S Baker; P Bleakley; G C Woodrow; W F Doe
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

2.  Genesis of ascites in ovarian cancer.

Authors:  K Hirabayashi; J Graham
Journal:  Am J Obstet Gynecol       Date:  1970-02-15       Impact factor: 8.661

3.  Gelatinases of metastatic cell lines of murine colonic carcinoma as detected by substrate-gel electrophoresis.

Authors:  S Yamagata; Y Ito; R Tanaka; S Shimizu
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

4.  Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate.

Authors:  H Nagase; J J Enghild; K Suzuki; G Salvesen
Journal:  Biochemistry       Date:  1990-06-19       Impact factor: 3.162

5.  Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells.

Authors:  M Nakajima; D Lotan; M M Baig; R M Carralero; W R Wood; M J Hendrix; R Lotan
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

6.  Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase.

Authors:  M Nakajima; T Irimura; N Di Ferrante; G L Nicolson
Journal:  J Biol Chem       Date:  1984-02-25       Impact factor: 5.157

Review 7.  Collagenolytic mechanisms in tumor cell invasion.

Authors:  D E Woolley
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 8.  Heparanases and tumor metastasis.

Authors:  M Nakajima; T Irimura; G L Nicolson
Journal:  J Cell Biochem       Date:  1988-02       Impact factor: 4.429

Review 9.  Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion.

Authors:  R Khokha; D T Denhardt
Journal:  Invasion Metastasis       Date:  1989

10.  Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.

Authors:  H Kobayashi; H Shinohara; J Gotoh; M Fujie; S Fujishiro; T Terao
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  5 in total

1.  Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent.

Authors:  Liora Shiftan; Michal Neeman
Journal:  Contrast Media Mol Imaging       Date:  2006 May-Jun       Impact factor: 3.161

Review 2.  Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

Review 3.  Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.

Authors:  Yasar Hoosen; Priyamvada Pradeep; Pradeep Kumar; Lisa C du Toit; Yahya E Choonara; Viness Pillay
Journal:  Int J Mol Sci       Date:  2018-03-04       Impact factor: 5.923

4.  Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure.

Authors:  Ilana Weiss; Claes G Trope; Reuven Reich; Ben Davidson
Journal:  Int J Mol Sci       Date:  2012-10-10       Impact factor: 5.923

Review 5.  Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines.

Authors:  Yadollah Omidi; Jaleh Barar
Journal:  Bioimpacts       Date:  2014-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.